Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Heichinger

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Frontiers in Oncology|March 28, 2025
Mapping MAGE-A4 expression in solid cancers for targeted therapiesChristin Habigt, Sylvie Rottey, Iben Spanggaard, et al.
Nature Medicine|April 20, 2026
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trialIgnacio Melero, Tamara Tanos, Emiliano Calvo Aller, et al.
Neuro-Oncology Advances|August 22, 2025
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastomaJames R Whittle, Maria Vieito, Kristoffer Rohrberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanomaElena Garralda, Christoph Markert, Victor Moreno, et al.
Journal for Immunotherapy of Cancer|June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumorsKristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
Journal for Immunotherapy of Cancer|April 9, 2026
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib studyJose Luis Perez-Gracia, Begoña Mellado, Aaron Richard Hansen, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Frontiers in Oncology|March 28, 2025
Mapping MAGE-A4 expression in solid cancers for targeted therapiesChristin Habigt, Sylvie Rottey, Iben Spanggaard, et al.
Nature Medicine|April 20, 2026
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trialIgnacio Melero, Tamara Tanos, Emiliano Calvo Aller, et al.
Neuro-Oncology Advances|August 22, 2025
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastomaJames R Whittle, Maria Vieito, Kristoffer Rohrberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanomaElena Garralda, Christoph Markert, Victor Moreno, et al.
Journal for Immunotherapy of Cancer|June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumorsKristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
Journal for Immunotherapy of Cancer|April 9, 2026
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib studyJose Luis Perez-Gracia, Begoña Mellado, Aaron Richard Hansen, et al.
Pageof 2